In this work, we have demonstrated that patients with intermediate-risk thyroid carcinoma, treated with thyroid surgical resection and RIT, have a significantly higher risk of displaying an LER to radioiodine treatment when harboring a BRAF mutation (p = 0.001). This evidence concerns the gene BRAF and thyroiditis.